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Much evidence points towards inflammation as a key regulatory 
process linking cardiovascular risk factors for atherosclerosis 
and its complications to an altered arterial biology.1 Systemic 
inflammatory conditions such as SLE, rheumatoid arthritis, 
Sjögren, systemic sclerosis, vasculitis, Crohn’s disease and 
others are also associated with enhanced atherosclerosis.
There are many reports of the relationship between biomarkers of 
inflammation and cardiovascular risk. Generally, the clinical use 
of a biomarker depends on many factors (e.g. ease of measuring, 
cost, reproducibility etc). There are currently many such biomarkers 
of inflammation for diagnostic use such as myeloperoxidase, 
lipoprotein A2, interleukin -6 and C-reactive protein (CRP). CRP 
measured by a highly sensitive assay (hs CRP) has emerged as 
a leading biomarker of inflammation. Quite a number of large-
scale prospective cohort studies have shown that CRP predicts 
incident myocardial infarction, stroke and cardiovascular death. 
CRP, along with parental history improves the prediction ability of 
the traditional Framingham risk score. There are strong indications 
that in people who fall in the intermediate risk category according 
to the Framingham risk score, an elevated CRP will push them 
into a higher risk category. Although there is strong evidence 
of association between CRP and cardiovascular risk, there is 
doubt whether CRP actually is causally linked to atherosclerosis. 
The question arises – should CRP be used to monitor therapy 
in a way that would improve clinical effectiveness of therapy? 
There is some evidence to show that if CRP, together with LDL-
cholesterol are lowered, the effectiveness will increase. In the 
Prove IT-Timi 22 trial, clinical outcomes were best among statin 
treated patients who not only achieved LDL-cholesterol levels 
below 1.8 mmol/L but who also achieved CRP levels below 
2 mg/L.2
The Jupiter trial tested this hypothesis prospectively. Maximum 
treatment benefit occurred with reduction of both LDL-cholesterol 
and CRP levels.3 Is there a future of targeting inflammation in 
atherosclerosis beyond statins? Systemic anti-inflammatory 
therapies such as corticosteroids and non-steroidal anti-
flammatory drugs are not suitable in atherosclerosis; in fact, they 
may increase thrombotic cardiovascular events.
There are indications that immuno-modulatory drugs, so called 
biologicals e.g. Blockade of Tumour necrosis factor-alpha may 
improve endothelial function and thus reduce the atherosclerotic 
risk in rheumatoid arthritis.
Inhibitors of lipoprotein associated phospholipase A2 are being 
tested. Vaccination with lipoprotein peptides is also being 
considered. Advances in our understanding of inflammation are 
being made rapidly and hopefully future therapeutic modalities 
will evolve.
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